Targeted pill may shrink lung tumors before surgery in new trial
NCT ID NCT05740943
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether taking the targeted drug lorlatinib for three months before surgery can shrink tumors in people with stage III ALK-positive non-small cell lung cancer. The study involves 48 participants and aims to see if the drug can eliminate all signs of cancer in the removed tissue. It also explores how genetic testing in the blood can help guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lorlatinib (a targeted cancer pill)
What this could lead to
If successful, this approach could shrink advanced lung tumors enough to allow surgery, potentially improving long-term control of the disease.
What could go wrong
This is a small, early-phase trial with only 48 participants. It is not yet proven to work better than standard treatment, and side effects from lorlatinib or surgery are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SURGERY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
-
Guangzhou Twelfth People's Hospital
Guangzhou, Guangdong, China
-
Peking Union Medical College Hospital
Beijin, Beijin, 100730, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China